hVIVO PLC HVO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBP 0.32
- Day Range
- GBP 0.32–0.32
- 52-Week Range
- GBP 0.16–0.36
- Bid/Ask
- GBP 0.32 / GBP 0.37
- Market Cap
- GBP 217.72 Mil
- Volume/Avg
- 13 / 1,721
Key Statistics
- Price/Earnings (Normalized)
- 21.40
- Price/Sales
- 3.41
- Dividend Yield (Trailing)
- 0.73%
- Dividend Yield (Forward)
- 0.85%
- Total Yield
- 0.73%
Company Profile
hVIVO PLC is a European-focused, rare, and orphan drug consulting services platform. The principal activity of the Group is that of a rapidly growing specialist CRO pharmaceutical services company, which involves the testing of vaccines and antivirals using human-challenge clinical trials. The group is also engaged in Venn Life Sciences’ Clinical Research Division, providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 274
- Website
- https://www.hvivo.com
Comparables
Valuation
|
Metric
|
HVO
|
ERGO
|
BVXP
|
|---|---|---|---|
Price/Earnings (Normalized) | 21.40 | 31.20 | 27.69 |
Price/Book Value | 5.50 | 8.19 | 19.86 |
Price/Sales | 3.41 | 4.55 | 16.98 |
Price/Cash Flow | 14.54 | 35.25 | 25.27 |
Price/Earnings
HVO
ERGO
BVXP
Financial Strength
|
Metric
|
HVO
|
ERGO
|
BVXP
|
|---|---|---|---|
Quick Ratio | 1.43 | 1.72 | 6.69 |
Current Ratio | 1.48 | 1.79 | 7.04 |
Interest Coverage | 65.30 | 30.39 | — |
Quick Ratio
HVO
ERGO
BVXP
Profitability
|
Metric
|
HVO
|
ERGO
|
BVXP
|
|---|---|---|---|
Return on Assets (Normalized) | 13.83% | 17.36% | 68.76% |
Return on Equity (Normalized) | 34.06% | 28.99% | 77.21% |
Return on Invested Capital (Normalized) | 25.17% | 26.30% | 76.10% |
Return on Assets
HVO
ERGO
BVXP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gtwcwngbx | Dtkd | $605.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rtwcrssl | Fscssy | $116.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vhbktlr | Yqrqkv | $108.5 Bil | |
MRNA
| Moderna Inc | Xpydmlwn | Snwr | $62.9 Bil | |
BNTX
| BioNTech SE ADR | Vzjhrmy | Tkzr | $23.9 Bil | |
ARGX
| argenx SE ADR | Lqrslkbj | Nzc | $21.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qllnnrww | Tjxcvy | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tfyzwtnj | Bvcnj | $14.3 Bil | |
INCY
| Incyte Corp | Fdwnhmtx | Pkldt | $12.9 Bil | |
UTHR
| United Therapeutics Corp | Jbnrgjrv | Jchr | $12.1 Bil |